Patient demographics and clinical characteristics by treatment arm
| . | Arm A: HU (n = 86) . | Arm B: PEG (n = 82) . | Total (N = 168) . |
|---|---|---|---|
| Age, y | 63 (18-87) | 60 (19-79) | 61 (18-87) |
| Race, % | |||
| White | 70 (84) | 76 (94) | 146 (89) |
| African American | 5 (6) | 3 (4) | 8 (5) |
| Asian | 3 (4) | 0 | 3 (2) |
| Hawaiian/Pacific Islander | 1 (1) | 0 | 1 (1) |
| Not reported | 7 (8) | 3 (4) | 10 (6) |
| Gender, % | |||
| Female | 37 (44) | 33 (40) | 70 (42) |
| Male | 49 (56) | 49 (60) | 98 (58) |
| MPN subtype, % | |||
| ET | 42 (49) | 39 (48) | 81 (48) |
| PV | 44 (51) | 43 (52) | 87 (52) |
| ECOG, % | |||
| 0 | 72 (84) | 65 (79) | 137 (82) |
| 1 | 13 (15) | 15 (18) | 28 (17) |
| 2+ | 1 (1) | 2 (2) | 3 (2) |
| Disease duration, mo | 3.1 (1-84.2) | 2.6 (0.4-41.7) | 2.8 (0.4-84.2) |
| Age >60 y, % | 56 (65) | 42 (51) | 98 (58) |
| History of thrombosis, % | 20 (23) | 26 (32) | 46 (27) |
| ET, % | 8 (19) | 13 (33) | 21 (26) |
| PV, % | 12 (27) | 13 (30) | 25 (29) |
| Aspirin use, % | 72 (84) | 64 (78) | 136 (81) |
| Anticoagulant use, % | 5 (6) | 6 (7) | 11 (7) |
| Spleen length by ultrasound, cm* | 12.5 (2.1-20) | 12.5 (6.5-22) | 12.5 (2.1-22) |
| Leukocytes, × 109L | 9.2 (3.0-34.4) | 8.6 (4.0-24.8) | 8.8 (3.0-34.4) |
| Hemoglobin, g/dL | 14.3 (11.3-16.4) | 14.6 (8.4-16.6) | 14.5 (8.4-16.6) |
| Hematocrit, % | 43.1 (40-70.2) | 43.8 (40-61.9) | 43.5 (40-70.2) |
| Platelets ×109/L | 612 (112-1444) | 602 (112-1662) | 606 (112-1662) |
| JAK2V617F, %† | 68 (92) | 65 (89) | 133 (91) |
| CALR exon 9, %† | 4 (5) | 7 (10) | 11 (8) |
| MPLW515L/K, %† | 3 (4) | 2 (3) | 5 (3) |
| Driver mutation present, %† | 71 (96) | 69 (95) | 140 (95) |
| . | Arm A: HU (n = 86) . | Arm B: PEG (n = 82) . | Total (N = 168) . |
|---|---|---|---|
| Age, y | 63 (18-87) | 60 (19-79) | 61 (18-87) |
| Race, % | |||
| White | 70 (84) | 76 (94) | 146 (89) |
| African American | 5 (6) | 3 (4) | 8 (5) |
| Asian | 3 (4) | 0 | 3 (2) |
| Hawaiian/Pacific Islander | 1 (1) | 0 | 1 (1) |
| Not reported | 7 (8) | 3 (4) | 10 (6) |
| Gender, % | |||
| Female | 37 (44) | 33 (40) | 70 (42) |
| Male | 49 (56) | 49 (60) | 98 (58) |
| MPN subtype, % | |||
| ET | 42 (49) | 39 (48) | 81 (48) |
| PV | 44 (51) | 43 (52) | 87 (52) |
| ECOG, % | |||
| 0 | 72 (84) | 65 (79) | 137 (82) |
| 1 | 13 (15) | 15 (18) | 28 (17) |
| 2+ | 1 (1) | 2 (2) | 3 (2) |
| Disease duration, mo | 3.1 (1-84.2) | 2.6 (0.4-41.7) | 2.8 (0.4-84.2) |
| Age >60 y, % | 56 (65) | 42 (51) | 98 (58) |
| History of thrombosis, % | 20 (23) | 26 (32) | 46 (27) |
| ET, % | 8 (19) | 13 (33) | 21 (26) |
| PV, % | 12 (27) | 13 (30) | 25 (29) |
| Aspirin use, % | 72 (84) | 64 (78) | 136 (81) |
| Anticoagulant use, % | 5 (6) | 6 (7) | 11 (7) |
| Spleen length by ultrasound, cm* | 12.5 (2.1-20) | 12.5 (6.5-22) | 12.5 (2.1-22) |
| Leukocytes, × 109L | 9.2 (3.0-34.4) | 8.6 (4.0-24.8) | 8.8 (3.0-34.4) |
| Hemoglobin, g/dL | 14.3 (11.3-16.4) | 14.6 (8.4-16.6) | 14.5 (8.4-16.6) |
| Hematocrit, % | 43.1 (40-70.2) | 43.8 (40-61.9) | 43.5 (40-70.2) |
| Platelets ×109/L | 612 (112-1444) | 602 (112-1662) | 606 (112-1662) |
| JAK2V617F, %† | 68 (92) | 65 (89) | 133 (91) |
| CALR exon 9, %† | 4 (5) | 7 (10) | 11 (8) |
| MPLW515L/K, %† | 3 (4) | 2 (3) | 5 (3) |
| Driver mutation present, %† | 71 (96) | 69 (95) | 140 (95) |